Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

ClinicalTrials.gov ID: NCT04092673

Public ClinicalTrials.gov record NCT04092673. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.

Study identification

NCT ID: NCT04092673
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Effector Therapeutics; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Solid Tumor, Adult

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 24, 2019
Primary completion: Dec 30, 2024
Completion: Mar 30, 2025
Last update posted: May 20, 2024

2019 – 2025

United States locations

U.S. sites: 14
U.S. states: 8
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of Southern California	Los Angeles	California	90033	Recruiting
Valkyrie Clinical Trials	Los Angeles	California	90067	Recruiting
Hoag Memorial Hospital Presbyterian	Newport Beach	California	92663	Completed
Stanford University	Palo Alto	California	94304	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada	89169	Completed
Memorial Sloan Kettering Cancer Center- Monmouth	Middletown	New Jersey	07748	Recruiting
Memorial Sloan Kettering Cancer Center- Commack	Commack	New York	11725	Recruiting
Memorial Sloan Kettering Cancer Center- Westchester	Harrison	New York	10604	Recruiting
Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care	New York	New York	11101	Recruiting
University of Toledo Medical Center	Toledo	Ohio	43614	Completed
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
New Experimental Therapeutics of San Antonio - NEXT Oncology	San Antonio	Texas	78229	Completed
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04092673, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 20, 2024 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04092673 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →